Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO
· Real-Time Price · USD
5.53
0.18 (3.36%)
At close: Oct 15, 2025, 3:59 PM
5.54
0.18%
After-hours: Oct 15, 2025, 04:34 PM EDT
3.36% (1D)
| Bid | 5.35 |
| Market Cap | 283.56M |
| Revenue (ttm) | 5.18M |
| Net Income (ttm) | 57.24M |
| EPS (ttm) | 0.64 |
| PE Ratio (ttm) | 8.64 |
| Forward PE | 180.33 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 5.54 |
| Volume | 1,196,624 |
| Avg. Volume (20D) | 829,393 |
| Open | 5.37 |
| Previous Close | 5.35 |
| Day's Range | 5.35 - 5.68 |
| 52-Week Range | 3.93 - 7.54 |
| Beta | 1.42 |
| Ex-Dividend Date | n/a |
About ABEO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ABEO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ABEO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsAbeona Therapeutics Inc. is scheduled to release its earnings on
Nov 13, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+10.21%
Abeona Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
5 months ago
+23.77%
Abeona Therapeutics shares are trading higher after HC Wainwright & Co. raised its price target on the stock from $15 to $20. Additionally, the stock may be moving on continued strength after announcing yesterday FDA for its gene therapy.
2 months ago · seekingalpha.com
Abeona Therapeutics: AAV204 Capsid Could Be Next Growth Prospect Beyond ZevaskynThe FDA's approval and commercial launch of Abeona Therapeutics Inc.'s Zevaskyn for RDEB, plus $155M PRV sale, provides strong financial runway for company for two years. AIM AAV204 capsid platform an...